Your Cart

Market Herald Interview

Market Herald Interview

In May, Imagion signed a collaboration agreement with Siemens Healthineers to explore the utility of our MagSense nanoparticles as a contrast agent in MRI scanning. This collaboration will allow us to explore additional ways of commercializing our technology and could transform how MRI is used to diagnose cancer in the future.

Watch CEO Bob Proulx discuss the significance of the collaboration with the Market Herald:

Related Articles

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.